- Home
- DNTH vs CDMO Comparison
DNTH vs CDMO Comparison
Compare DNTH & CDMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNTH
- CDMO
- Stock Information
- Founded
- DNTH 2015
- CDMO 1981
- Country
- DNTH United States
- CDMO United States
- Employees
- DNTH N/A
- CDMO N/A
- Industry
- DNTH Biotechnology: Pharmaceutical Preparations
- CDMO Biotechnology: Pharmaceutical Preparations
- Sector
- DNTH Health Care
- CDMO Health Care
- Exchange
- DNTH Nasdaq
- CDMO Nasdaq
- Market Cap
- DNTH 711.2M
- CDMO 793.8M
- IPO Year
- DNTH N/A
- CDMO N/A
- Fundamental
- Price
- DNTH $21.66
- CDMO $12.46
- Analyst Decision
- DNTH Strong Buy
- CDMO Hold
- Analyst Count
- DNTH 9
- CDMO 3
- Target Price
- DNTH $46.43
- CDMO $12.25
- AVG Volume (30 Days)
- DNTH 285.9K
- CDMO 1.3M
- Earning Date
- DNTH 11-07-2024
- CDMO 12-10-2024
- Dividend Yield
- DNTH N/A
- CDMO N/A
- EPS Growth
- DNTH N/A
- CDMO N/A
- EPS
- DNTH N/A
- CDMO N/A
- Revenue
- DNTH $5,366,000.00
- CDMO $150,445,000.00
- Revenue This Year
- DNTH $100.14
- CDMO $19.05
- Revenue Next Year
- DNTH N/A
- CDMO $20.88
- P/E Ratio
- DNTH N/A
- CDMO N/A
- Revenue Growth
- DNTH 51.41
- CDMO 6.75
- 52 Week Low
- DNTH $14.82
- CDMO $5.90
- 52 Week High
- DNTH $33.77
- CDMO $12.48
- Technical
- Relative Strength Index (RSI)
- DNTH 45.12
- CDMO 66.88
- Support Level
- DNTH $18.72
- CDMO $12.37
- Resistance Level
- DNTH $28.65
- CDMO $12.45
- Average True Range (ATR)
- DNTH 2.31
- CDMO 0.05
- MACD
- DNTH -0.33
- CDMO -0.01
- Stochastic Oscillator
- DNTH 32.14
- CDMO 100.00
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
About CDMO Avid Bioservices Inc.
Avid Bioservices Inc is a clinical-stage biopharmaceutical company focused on the development and Current Good Manufacturing Practices (CGMP) of biopharmaceutical products derived from mammalian cell culture. Its business is organized into one reportable operating segment which is contract manufacturing and development services segment. Its services include clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. The company also provides a variety of process development services including cell line development, upstream and downstream development and optimization, analytical method development, testing and characterization.